Table of Contents

Research Articles: Therapeutics, Targets, and Development

• Research Articles: Therapeutics, Targets, and Development

  Effect of population and gender on chemotherapeutic agent–induced cytotoxicity

  Rong Stephanie Huang, Emily O. Kistner, Wasim K. Bleibel, Sunita J. Shukla and M. Eileen Dolan

  Mol Cancer Ther January 1 2007 6 (1) 31-36; DOI:10.1158/1535-7163.MCT-06-0591

  
  
• Research Articles: Therapeutics, Targets, and Development

  Nuclear factor-κB p65 small interfering RNA or proteasome inhibitor bortezomib sensitizes head and neck squamous cell carcinomas to classic histone deacetylase inhibitors and novel histone deacetylase inhibitor PXD101

  Jianming Duan, Jay Friedman, Liesl Nottingham, Zhong Chen, Gulshan Ara and Carter Van Waes

  Mol Cancer Ther January 1 2007 6 (1) 37-50; DOI:10.1158/1535-7163.MCT-05-0285

  
  
• Research Articles: Therapeutics, Targets, and Development

  Suberoylanilide hydroxamic acid (vorinostat) represses androgen receptor expression and acts synergistically with an androgen receptor antagonist to inhibit prostate cancer cell proliferation

  Deborah L. Marrocco, Wayne D. Tilley, Tina Bianco-Miotto, Andreas Evdokiou, Howard I. Scher, Richard A. Rifkind, Paul A. Marks, Victoria M. Richon and Lisa M. Butler

  Mol Cancer Ther January 1 2007 6 (1) 51-60; DOI:10.1158/1535-7163.MCT-06-0144

  
  
• Research Articles: Therapeutics, Targets, and Development

  Epidermal growth factor receptor inhibition sensitizes renal cell carcinoma cells to the cytotoxic effects of bortezomib

  Jiabin An and Matthew B. Rettig

  Mol Cancer Ther January 1 2007 6 (1) 61-69; DOI:10.1158/1535-7163.MCT-06-0255

  
  
• Research Articles: Therapeutics, Targets, and Development

  Antitumor effect of the histone deacetylase inhibitor LAQ824 in combination with 13-cis-retinoic acid in human malignant melanoma

  Yukihiko Kato, Brenda C. Salumbides, Xiao-Fei Wang, David Z. Qian, Simon Williams, Yongfeng Wei, Tolib B. Sanni, Peter Atadja and Roberto Pili

  Mol Cancer Ther January 1 2007 6 (1) 70-81; DOI:10.1158/1535-7163.MCT-06-0125

  
  
• Research Articles: Therapeutics, Targets, and Development

  Combination treatment with arsenic trioxide and phytosphingosine enhances apoptotic cell death in arsenic trioxide–resistant cancer cells

  Moon-Taek Park, Young-Hee Kang, In-Chul Park, Chun-Ho Kim, Yun-Sil Lee, Hee Yong Chung and Su-Jae Lee

  Mol Cancer Ther January 1 2007 6 (1) 82-92; DOI:10.1158/1535-7163.MCT-06-0349

  
  
• Research Articles: Therapeutics, Targets, and Development

  Sensitivity to pertuzumab (2C4) in ovarian cancer models: cross-talk with estrogen receptor signaling

  Peter Mullen, David A. Cameron, Max Hasmann, John F. Smyth and Simon P. Langdon

  Mol Cancer Ther January 1 2007 6 (1) 93-100; DOI:10.1158/1535-7163.MCT-06-0401

  
  
• Research Articles: Therapeutics, Targets, and Development

  Knock-down of Bcl-2 by antisense oligodeoxynucleotides induces radiosensitization and inhibition of angiogenesis in human PC-3 prostate tumor xenografts

  Satoshi Anai, Steve Goodison, Kathleen Shiverick, Yoshihiko Hirao, Bob D. Brown and Charles J. Rosser

  Mol Cancer Ther January 1 2007 6 (1) 101-111; DOI:10.1158/1535-7163.MCT-06-0367

  
  
• Research Articles: Therapeutics, Targets, and Development

  Deactivation of Akt and STAT3 signaling promotes apoptosis, inhibits proliferation, and enhances the sensitivity of hepatocellular carcinoma cells to an anticancer agent, Atiprimod

  Sweeta R. Choudhari, Muhammad A. Khan, Genesis Harris, Donald Picker, Gary S. Jacob, Timothy Block and Kunwar Shailubhai

  Mol Cancer Ther January 1 2007 6 (1) 112-121; DOI:10.1158/1535-7163.MCT-06-0561

  
  
• Research Articles: Therapeutics, Targets, and Development

  MRP8/ABCC11 directly confers resistance to 5-fluorouracil

  Tetsuya Oguri, Yuji Bessho, Hiroyuki Achiwa, Hiroaki Ozasa, Ken Maeno, Hiroyoshi Maeda, Shigeki Sato and Ryuzo Ueda

  Mol Cancer Ther January 1 2007 6 (1) 122-127; DOI:10.1158/1535-7163.MCT-06-0529

  
  
• Research Articles: Therapeutics, Targets, and Development

  The role of spermidine/spermine N¹-acetyltransferase in determining response to chemotherapeutic agents in colorectal cancer cells

  Wendy L. Allen, Estelle G. McLean, John Boyer, Andrea McCulla, Peter M. Wilson, Vicky Coyle, Daniel B. Longley, Robert A. Casero Jr. and Patrick G. Johnston

  Mol Cancer Ther January 1 2007 6 (1) 128-137; DOI:10.1158/1535-7163.MCT-06-0303

  
  
• Research Articles: Therapeutics, Targets, and Development

  Targeted inhibition of the extracellular signal-regulated kinase kinase pathway with AZD6244 (ARRY-142886) in the treatment of hepatocellular carcinoma

  Hung Huynh, Khee Chee Soo, Pierce K.H. Chow and Evelyn Tran

  Mol Cancer Ther January 1 2007 6 (1) 138-146; DOI:10.1158/1535-7163.MCT-06-0436

  
  
• Research Articles: Therapeutics, Targets, and Development

  Cell cycle phenotype-based optimization of G₂-abrogating peptides yields CBP501 with a unique mechanism of action at the G₂ checkpoint

  Shi-Ken Sha, Takuji Sato, Hidetaka Kobayashi, Machiyo Ishigaki, Sayaka Yamamoto, Hitoshi Sato, Asako Takada, Sigetosi Nakajyo, Yasuo Mochizuki, Jonathan M. Friedman, Fong-Chi Cheng, Takashi Okura, Ryohei Kimura, Donald W. Kufe, Daniel D. VonHoff and Takumi Kawabe

  Mol Cancer Ther January 1 2007 6 (1) 147-153; DOI:10.1158/1535-7163.MCT-06-0371

  
  
• Research Articles: Therapeutics, Targets, and Development

  Pharmacodynamic characterization of chemopreventive triterpenoids as exceptionally potent inducers of Nrf2-regulated genes

  Melinda S. Yates, Masafumi Tauchi, Fumiki Katsuoka, Kathleen C. Flanders, Karen T. Liby, Tadashi Honda, Gordon W. Gribble, Delinda A. Johnson, Jeffrey A. Johnson, Neal C. Burton, Tomás R. Guilarte, Masayuki Yamamoto, Michael B. Sporn and Thomas W. Kensler

  Mol Cancer Ther January 1 2007 6 (1) 154-162; DOI:10.1158/1535-7163.MCT-06-0516

  
  
• Research Articles: Therapeutics, Targets, and Development

  Characterization of a potent and selective small-molecule inhibitor of the PIM1 kinase

  Sheldon Holder, Marina Zemskova, Chao Zhang, Maryam Tabrizizad, Ryan Bremer, Jonathan W. Neidigh and Michael B. Lilly

  Mol Cancer Ther January 1 2007 6 (1) 163-172; DOI:10.1158/1535-7163.MCT-06-0397

  
  
• Research Articles: Therapeutics, Targets, and Development

  HU-331, a novel cannabinoid-based anticancer topoisomerase II inhibitor

  Natalya M. Kogan, Michael Schlesinger, Esther Priel, Ruth Rabinowitz, Eduard Berenshtein, Mordechai Chevion and Raphael Mechoulam

  Mol Cancer Ther January 1 2007 6 (1) 173-183; DOI:10.1158/1535-7163.MCT-06-0039

  
  
• Research Articles: Therapeutics, Targets, and Development

  Eupalmerin acetate, a novel anticancer agent from Caribbean gorgonian octocorals, induces apoptosis in malignant glioma cells via the c-Jun NH₂-terminal kinase pathway

  Arifumi Iwamaru, Eiji Iwado, Seiji Kondo, Robert A. Newman, Burnilda Vera, Abimael D. Rodríguez and Yasuko Kondo

  Mol Cancer Ther January 1 2007 6 (1) 184-192; DOI:10.1158/1535-7163.MCT-06-0422

  
  
• Research Articles: Therapeutics, Targets, and Development

  D-501036, a novel selenophene-based triheterocycle derivative, exhibits potent in vitro and in vivo antitumoral activity which involves DNA damage and ataxia telangiectasia–mutated nuclear protein kinase activation

  Shin-Hun Juang, Chia-Chi Lung, Pi-Chen Hsu, Kuo-Shun Hsu, Yu-Chen Li, Pao-Chiung Hong, Her-Shyong Shiah, Ching-Chuan Kuo, Ching-Wei Huang, Yu-Chin Wang, Leeyuan Huang, Tom S. Chen, Shyh-Fong Chen, Kuo-Chu Fu, Cheng-Li Hsu, Meng-Ju Lin, Ching-jer Chang, Curtis L. Ashendel, Thomas C.K. Chan, Kai-Ming Chou and Jang-Yang Chang

  Mol Cancer Ther January 1 2007 6 (1) 193-202; DOI:10.1158/1535-7163.MCT-06-0482

  
  
• Research Articles: Therapeutics, Targets, and Development

  Preclinical evaluation of ²¹³Bi-labeled plasminogen activator inhibitor type 2 in an orthotopic murine xenogenic model of human breast carcinoma

  Tamantha K. Stutchbury, Fares Al-ejeh, Gillian E. Stillfried, David R. Croucher, John Andrews, David Irving, Matthew Links and Marie Ranson

  Mol Cancer Ther January 1 2007 6 (1) 203-212; DOI:10.1158/1535-7163.MCT-06-0264

  
  
• Research Articles: Therapeutics, Targets, and Development

  XR5944: A potent inhibitor of estrogen receptors

  Chandanamali Punchihewa, Adrian De Alba, Neil Sidell and Danzhou Yang

  Mol Cancer Ther January 1 2007 6 (1) 213-219; DOI:10.1158/1535-7163.MCT-06-0392

  
  
• Research Articles: Therapeutics, Targets, and Development

  Chrysin inhibits expression of hypoxia-inducible factor-1α through reducing hypoxia-inducible factor-1α stability and inhibiting its protein synthesis

  Beibei Fu, Jing Xue, Zhaodong Li, Xianglin Shi, Bing-Hua Jiang and Jing Fang

  Mol Cancer Ther January 1 2007 6 (1) 220-226; DOI:10.1158/1535-7163.MCT-06-0526

  
  
• Research Articles: Therapeutics, Targets, and Development

  Adenovirus type 5 E1A gene therapy for ovarian clear cell carcinoma: a potential treatment strategy

  Hiroaki Itamochi, Junzo Kigawa, Yasunobu Kanamori, Tetsuro Oishi, Chandra Bartholomeusz, Rita Nahta, Francisco J. Esteva, Nour Sneige, Naoki Terakawa and Naoto T. Ueno

  Mol Cancer Ther January 1 2007 6 (1) 227-235; DOI:10.1158/1535-7163.MCT-05-0499

  
  
• Research Articles: Therapeutics, Targets, and Development

  Heat-inducible in vivo gene therapy of colon carcinoma by human mdr1 promoter–regulated tumor necrosis factor-α expression

  Wolfgang Walther, Franziska Arlt, Iduna Fichtner, Jutta Aumann, Ulrike Stein and Peter M. Schlag

  Mol Cancer Ther January 1 2007 6 (1) 236-243; DOI:10.1158/1535-7163.MCT-06-0070

  
  
• Research Articles: Therapeutics, Targets, and Development

  Pulmonary adenocarcinoma–targeted gene therapy by a cancer- and tissue-specific promoter system

  Takuya Fukazawa, Yutaka Maeda, Mary L. Durbin, Toru Nakai, Junji Matsuoka, Hirotoshi Tanaka, Yoshio Naomoto and Noriaki Tanaka

  Mol Cancer Ther January 1 2007 6 (1) 244-252; DOI:10.1158/1535-7163.MCT-06-0408

  
  
• Research Articles: Therapeutics, Targets, and Development

  Endothelin signaling in osteoblasts: global genome view and implication of the calcineurin/NFAT pathway

  Charles Van Sant, Gang Wang, Mark G. Anderson, Oscar J. Trask, Rick Lesniewski and Dimitri Semizarov

  Mol Cancer Ther January 1 2007 6 (1) 253-261; DOI:10.1158/1535-7163.MCT-06-0574

  
  
• Research Articles: Therapeutics, Targets, and Development

  The JAMM motif of human deubiquitinase Poh1 is essential for cell viability

  Melissa Gallery, Jonathan L. Blank, Yinghui Lin, Juan A. Gutierrez, Jacqueline C. Pulido, David Rappoli, Sunita Badola, Mark Rolfe and Kyle J. MacBeth

  Mol Cancer Ther January 1 2007 6 (1) 262-268; DOI:10.1158/1535-7163.MCT-06-0542

  
  
• Research Articles: Therapeutics, Targets, and Development

  Survivin depletion preferentially reduces the survival of activated K-Ras-transformed cells

  Aparna V. Sarthy, Susan E. Morgan-Lappe, Dorothy Zakula, Lawrence Vernetti, Mark Schurdak, Jeremy C.L. Packer, Mark G. Anderson, Senji Shirasawa, Takehiko Sasazuki and Stephen W. Fesik

  Mol Cancer Ther January 1 2007 6 (1) 269-276; DOI:10.1158/1535-7163.MCT-06-0560

  
  
• Research Articles: Therapeutics, Targets, and Development

  Molecular correlates of gefitinib responsiveness in human bladder cancer cells

  Marissa Shrader, Maria Simona Pino, Gordon Brown, Peter Black, Liana Adam, Menahse Bar-Eli, Colin P.N. Dinney and David J. McConkey

  Mol Cancer Ther January 1 2007 6 (1) 277-285; DOI:10.1158/1535-7163.MCT-06-0513

  
  
• Research Articles: Therapeutics, Targets, and Development

  Novel cell death pathways induced by N-(4-hydroxyphenyl)retinamide: therapeutic implications

  Roberta Venè, Giuseppe Arena, Alessandro Poggi, Cristina D'Arrigo, Michele Mormino, Douglas M. Noonan, Adriana Albini and Francesca Tosetti

  Mol Cancer Ther January 1 2007 6 (1) 286-298; DOI:10.1158/1535-7163.MCT-06-0346

  
  
• Research Articles: Therapeutics, Targets, and Development

  Hsp27 knockdown using nucleotide-based therapies inhibit tumor growth and enhance chemotherapy in human bladder cancer cells

  Masayuki Kamada, Alan So, Mototsugu Muramaki, Palma Rocchi, Eliana Beraldi and Martin Gleave

  Mol Cancer Ther January 1 2007 6 (1) 299-308; DOI:10.1158/1535-7163.MCT-06-0417

  
  
• Research Articles: Therapeutics, Targets, and Development

  Synergism between vitamin D and secreted protein acidic and rich in cysteine–induced apoptosis and growth inhibition results in increased susceptibility of therapy-resistant colorectal cancer cells to chemotherapy

  Farnaz Taghizadeh, Michelle J. Tang and Isabella T. Tai

  Mol Cancer Ther January 1 2007 6 (1) 309-317; DOI:10.1158/1535-7163.MCT-06-0517

  
  
• Research Articles: Therapeutics, Targets, and Development

  Pharmacologic inhibition of CDC25 phosphatases impairs interphase microtubule dynamics and mitotic spindle assembly

  Martine Cazales, Rose Boutros, Marie-Christine Brezak, Sophie Chaumeron, Grégoire Prevost and Bernard Ducommun

  Mol Cancer Ther January 1 2007 6 (1) 318-325; DOI:10.1158/1535-7163.MCT-06-0299

  
  
• Research Articles: Therapeutics, Targets, and Development

  The human IgM antibody SAM-6 induces tumor-specific apoptosis with oxidized low-density lipoprotein

  Stephanie Brändlein, Nicole Rauschert, Leo Rasche, Angela Dreykluft, Frank Hensel, Ernst Conzelmann, Hans-Konrad Müller-Hermelink and H. Peter Vollmers

  Mol Cancer Ther January 1 2007 6 (1) 326-333; DOI:10.1158/1535-7163.MCT-06-0399

  
  
• Research Articles: Therapeutics, Targets, and Development

  Antiproliferative activity of sulforaphane in Akt-overexpressing ovarian cancer cells

  Devyani Chaudhuri, Sandra Orsulic and Badithe T. Ashok

  Mol Cancer Ther January 1 2007 6 (1) 334-345; DOI:10.1158/1535-7163.MCT-06-0404

  
  
• Research Articles: Therapeutics, Targets, and Development

  Modulation of topoisomerase IIα expression by a DNA sequence-specific polyamide

  Daniel Hochhauser, Minal Kotecha, Caroline O'Hare, Peter J. Morris, Janet M. Hartley, Zarmeen Taherbhai, Dorothy Harris, Claudia Forni, Roberto Mantovani, Moses Lee and John A. Hartley

  Mol Cancer Ther January 1 2007 6 (1) 346-354; DOI:10.1158/1535-7163.MCT-06-0503

  
  
• Research Articles: Therapeutics, Targets, and Development

  Chemotherapeutic selectivity conferred by selenium: a role for p53-dependent DNA repair

  Joshua L. Fischer, Elaine M. Mihelc, Karen E. Pollok and Martin L. Smith

  Mol Cancer Ther January 1 2007 6 (1) 355-361; DOI:10.1158/1535-7163.MCT-06-0472

  
  
• Research Articles: Therapeutics, Targets, and Development

  Prodigiosin induces the proapoptotic gene NAG-1 via glycogen synthase kinase-3β activity in human breast cancer cells

  Vanessa Soto-Cerrato, Francesc Viñals, James R. Lambert, Julie A. Kelly and Ricardo Pérez-Tomás

  Mol Cancer Ther January 1 2007 6 (1) 362-369; DOI:10.1158/1535-7163.MCT-06-0266

  
  
• Research Articles: Therapeutics, Targets, and Development

  The role of autophagy in the death of L1210 leukemia cells initiated by the new antitumor agents, XK469 and SH80

  David Kessel, John J. Reiners Jr., Stuart T. Hazeldine, Lisa Polin and Jerome P. Horwitz

  Mol Cancer Ther January 1 2007 6 (1) 370-379; DOI:10.1158/1535-7163.MCT-05-0386

  
  
• Research Articles: Therapeutics, Targets, and Development

  A phase I trial of hyperthermia-induced interleukin-12 gene therapy in spontaneously arising feline soft tissue sarcomas

  Farzan Siddiqui, Chuan-Yuan Li, Susan M. LaRue, Jean M. Poulson, Paul R. Avery, Amy F. Pruitt, Xiuwu Zhang, Robert L. Ullrich, Donald E. Thrall, Mark W. Dewhirst and Marlene L. Hauck

  Mol Cancer Ther January 1 2007 6 (1) 380-389; DOI:10.1158/1535-7163.MCT-06-0342